Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Operations and Comprehensive Loss (Unaudited)

v3.19.3
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Operating costs and expenses:        
Research and development $ 1,036,689 $ 3,459,681 $ 6,044,580 $ 6,180,607
Patent costs 20,867 59,068 139,436 170,418
General and administrative 1,122,825 1,144,750 3,621,888 3,957,545
Total operating costs and expenses 2,180,381 4,663,499 9,805,904 10,308,570
Operating loss (2,180,381) (4,663,499) (9,805,904) (10,308,570)
Other income:        
Interest income 13,172 17,237 117,777 64,965
Total other income 13,172 17,237 117,777 64,965
Net loss (2,167,209) (4,646,263) (9,688,127) (10,243,605)
Other comprehensive income:        
Unrealized gain on debt securities 923
Comprehensive loss $ (2,167,209) $ (4,646,262) $ (9,687,204) $ (10,243,605)
Net loss per common share - basic and diluted $ (0.23) $ (0.86) $ (1.09) $ (2.00)
Weighted average common shares outstanding - basic and diluted 9,507,636 5,373,769 8,873,947 5,129,351